Annovis Bio Q2 FY26 net loss widens to $14.82 million; R&D expenses more than doubled to $12.01 million

• Annovis Bio posted a Q2 net loss of $14.82 million, widening from $6.22 million a year earlier; loss per share worsened to $0.40 from $0.32.
• R&D expense more than doubled to $12.01 million, lifting total operating costs to $14.38 million from $6.27 million.
• Cash and cash equivalents edged down to $18.73 million at June 30 from $19.53 million at Dec. 31, 2025.
• Pivotal Phase 3 early Alzheimer’s trial fully enrolled at 850 patients; 6-month database lock targeted for Q1 2027 with topline data expected then.
• Parkinson’s open-label extension enrolled 266 patients toward 500; CEO Maria Maccecchini said regulatory submission preparations have begun ahead of early-2027 results.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Annovis Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608140800PRIMZONEFULLFEED9810121) on August 14, 2026, and is solely responsible for the information contained therein.